Andreas Scheel

Andreas Scheel currently serves as the EVP Head of Cell Therapy at Evotec, leading research and development efforts in iPSC-based cell therapy for diabetes, immuno-oncology, and cardiovascular applications while also overseeing the site in Cologne. Previous roles at Evotec include EVP Global Head of Alliance Management, managing senior alliance managers and expanding strategic collaborations, and Executive Vice President In Vitro Biology, focusing on target identification and validation. Prior to returning to Evotec, Scheel held multiple director positions at Prosidion Ltd. and OSI Pharmaceuticals, concentrating on pharmacology and R&D related to diabetes and obesity. Scheel's career at Evotec began in 1997, progressing through various roles focused on assay development and cellular biology. Academic qualifications include a PhD in Cell Biology and Biochemistry from the Laboratory of Molecular Biology at the University of Cambridge and a Diploma in Biochemistry from the University of Tübingen.